Michelle Look, MD
Sports Medicine · San Diego, CANPI 1851402143
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Lilly USA, LLC at 55.0% of the total. 2025 is the largest year on record at $85,501, 7.3 times the $11,720 reported in 2019. Among sports medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $791.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$113K
- Boehringer Ingelheim$48K
- Eli Lilly$25K
- Novo Nordisk$19K
- Rhythm Pharmaceuticals, Inc.$239
- Kvk-tech, Inc.$143
- plus $355 from 11 others
Across 5 payments — averaging $3920.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$20K
What the payments were for
- Consulting fees$70,36034%
- Speaking & faculty fees$116,22156%
- Travel & lodging$13,0946%
- Food & beverage$5,9543%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 128 | $113,255 |
| Boehringer Ingelheim | 29 | $48,256 |
| Eli Lilly | 23 | $24,828 |
| Novo Nordisk | 56 | $18,740 |
| Rhythm Pharmaceuticals, Inc. | 5 | $239 |
| Kvk-tech, Inc. | 3 | $143 |
| Johnson & Johnson | 3 | $61 |
| Edwards Lifesciences | 1 | $52 |
| Pfizer | 2 | $49 |
| Currax Pharmaceuticals LLC | 2 | $44 |
| Hologic Sales And Service, LLC | 2 | $38 |
| Bioventus LLC | 1 | $25 |
| AbbVie | 1 | $22 |
| Intra-sana Laboratories | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$205,815 in reported general payments places this provider in the 90th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $126,561 |
| MounjaroTirzepatide | 85 | $111,927 |
| WegovySemaglutide | 17 | $22,338 |
| Bupropion XlBupropion Hcl | 60 | $1,742 |
| Topiramate | 180 | $1,700 |
| Metformin Hcl ErMetformin Hcl | 78 | $682 |
| Naltrexone Hcl | 12 | $576 |
| Ondansetron OdtOndansetron | 12 | $124 |
| Ondansetron Hcl | 14 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $18,740 | $148,898110 claims |
| Lilly USA, LLCMounjaro | $113,255 | $111,92785 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 662 sports medicine providers in California.
Other sports medicine in San Diego
- Tal DavidSan Diego$479K
- Okechukwu AnakwenzeSan Diego$304K
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Michael FreehillStanford$1.6M
- Allan MishraMenlo Park$1.5M
- Heinz Hoeneckela Jolla$1.4M
- Seth ShermanStanford$1.1M
- Stephan YacoubianBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.